证券代码：300804 证券简称：广康生化 公告编号：2025-045 广东广康生化科技股份有限公司 关于特定股东减持股份计划期限届满暨实施完毕的公告 股东深圳市华拓至远投资企业（有限合伙）、深圳市华拓至远贰号投资企业 （有限合伙）、深圳市华拓至远叁号投资企业（有限合伙）、共青城华拓至盈贰 号投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广东广康生化科技股份有限公司（以下简称"公司"或"发行人"）于 2025 年 6 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份预披露 公告》（公告编号：2025-022），公司股东深圳市华拓至远投资企业（有限合伙）、 深圳市华拓至远贰号投资企业（有限合伙）、深圳市华拓至远叁号投资企业（有限合 伙）、共青城华拓至盈贰号投资合伙企业（有限合伙）计划于减持计划公告之日起三 个交易日后的三个月内（即 2025 年 6 月 9 日-2025 年 9 月 8 日）以集中竞价交易或大 宗交易方式减持公司股份累计不超过 ...

Core Viewpoint - The company aims to become a leading agricultural chemical enterprise by integrating technological advancement, green values, and market returns into a positive cycle [1] Group 1: Company Vision and Strategy - The company is committed to creating a first-class agricultural chemical enterprise that is excellent, safe, environmentally friendly, and green [1] - The company does not choose between profitability and social responsibility but strives to ensure that technological progress and green values lead to market returns [1] Group 2: Product Development and Innovation - The company guides its research and development with green principles to ensure product safety and environmental friendliness [1] - The company leverages its technological advantages to create a differentiated and high-value product matrix [1] Group 3: Operational Management and Market Impact - The company has integrated a collaborative mechanism into its product layout and operational management to ensure performance growth while fulfilling environmental and social responsibilities [1] - The company plans to continue driving high-quality and sustainable development through green innovation, thereby rewarding the trust and support of investors [1]

Core Insights - Guangkang Biochemical reported a revenue of 399 million yuan for the first half of 2025, marking a year-on-year increase of 25.55% [1] - The net profit attributable to shareholders reached 29.01 million yuan, up 32.13% year-on-year, with a significant increase of 190% in net profit after deducting non-recurring gains [1] - The company achieved a positive net cash flow from operating activities of 38.67 million yuan, reversing from a negative position in the same period last year [1] Revenue Breakdown - The revenue from the raw material business was 329 million yuan, an increase of 18.26%, accounting for 82.42% of total revenue [1] - The formulation business generated 69.05 million yuan, showing a substantial growth of 82.64% [1] - The growth in revenue is attributed to increased sales of fungicide products and expansion in the formulation business, alongside cost reduction through optimized production processes [1] R&D and Innovation - The company invested 16.70 million yuan in R&D, reflecting an 11.83% increase year-on-year [2] - Guangkang Biochemical achieved certification for the GB/T29490-2023 intellectual property compliance management system and was recognized as a provincial-level technology center [2] - The company has developed expertise in key technology areas such as chlorination and diazotization, supporting continuous product upgrades [2] Market Strategy and Product Development - The company adheres to a "differentiated and niche" competition strategy, which has proven effective [2] - Core products such as Kexingdan and Mieqingdan received a 15-year renewal approval from the EU, with usage restrictions lifted, expected to boost overseas market demand [2] - The production lines for Mieqingdan at the Yingde base are operating at full capacity, while the Kexingdan production capacity at the Shaoguan base is continuously increasing [2] Product Portfolio and International Collaboration - Guangkang Biochemical is a major supplier of succinate dehydrogenase inhibitors and trichloromethyl sulfur fungicides, with a strong product matrix including Benfluralin, Thifensulfuron, and Kexingdan [2] - The company is the sole domestic producer of Toxaphene, and its clean production processes for Kexingdan and Mieqingdan have received national invention patents [2] - The company maintains stable collaborations with multinational agrochemical firms such as UPL and ADAMA, with products distributed in major markets like the US and EU [2]

Group 1 - Guangkang Biotech (300804.SZ) released its semi-annual report for 2025 on August 22, 2025, indicating that as of August 21, 2025, a total of 8 institutional investors disclosed holdings in Guangkang Biotech A-shares, with a total holding of 10.2497 million shares, accounting for 13.85% of the total share capital [1] - The institutional investors include several firms such as Yingde Zhongxing Investment Management Co., Ltd., Shenzhen Qianhai Ruihong Kaiyin Asset Management Co., Ltd., and Morgan Stanley & Co. International PLC, among others [1] - Compared to the previous quarter, the total proportion of institutional holdings decreased by 5.09 percentage points [1] Group 2 - In the public fund sector, one public fund, CITIC Prudential Multi-Strategy Mixed (LOF) A, was not disclosed in this period compared to the previous quarter [2] - Regarding foreign investment attitudes, one new foreign institution disclosed in this period is Morgan Stanley & Co. International PLC [2]

Core Insights - Guangkang Biochemical (300804.SZ) reported a total operating revenue of 399 million yuan for the first half of 2025, an increase of 81.18 million yuan compared to the same period last year, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders was 29.01 million yuan, up by 7.05 million yuan from the same period last year, reflecting a year-on-year increase of 32.13% [1] - The net cash inflow from operating activities was 38.67 million yuan, an increase of 39.09 million yuan compared to the same period last year [1] Financial Metrics - The latest gross profit margin is 23.63%, an increase of 0.22 percentage points from the previous quarter and up by 0.88 percentage points year-on-year [2] - The latest return on equity (ROE) is 2.14%, an increase of 0.46 percentage points compared to the same period last year [2] - The diluted earnings per share (EPS) is 0.39 yuan, an increase of 0.09 yuan year-on-year, representing a growth of 31.18% [2] - The total asset turnover ratio is 0.19 times, an increase of 0.03 times year-on-year, reflecting a growth of 15.08% [2] - The inventory turnover ratio is 1.82 times, an increase of 0.40 times compared to the same period last year, representing a year-on-year growth of 28.46% [2] Shareholder Information - The number of shareholders is 10,800, with the top ten shareholders holding a total of 52.54 million shares, accounting for 71.00% of the total share capital [2] - The largest shareholder is Cai Danqun, holding 34.8% of the shares [2] Debt Metrics - The latest debt-to-asset ratio is 35.92% [3]

Core Viewpoint - Guangkang Biochemical reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the industry [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 399 million yuan, representing a year-on-year increase of 25.55% [2] - The net profit attributable to shareholders was around 29.01 million yuan, reflecting a year-on-year growth of 32.13% [2] - Basic earnings per share were reported at 0.3921 yuan, which is an increase of 31.18% compared to the previous year [2]

Core Viewpoint - Guangkang Biochemical (300804) announced the appointment of three new vice presidents, indicating a strategic move to strengthen its management team [1] Group 1 - The board of directors of Guangkang Biochemical approved the hiring of Mr. Wang Shiyin, Mr. Che Lin, and Mr. Feng Weiguo as vice presidents [1]

Core Insights - Guangkang Biochemical reported a revenue of 398,931,436.58 yuan for the first half of 2025, representing a year-on-year growth of 25.55% [2] - The net profit attributable to shareholders of the listed company was 29,013,888.44 yuan, showing a year-on-year increase of 32.13% [2] Financial Performance - Revenue for the first half of 2025: 398,931,436.58 yuan, up 25.55% year-on-year [2] - Net profit for the first half of 2025: 29,013,888.44 yuan, up 32.13% year-on-year [2]

Core Viewpoint - The company, Guangdong Guokang Biochemical Technology Co., Ltd., aims to continue its foreign exchange derivatives trading to mitigate risks associated with currency fluctuations and enhance financial stability [1][10]. Group 1: Purpose of Foreign Exchange Derivatives Trading - The primary objective of engaging in foreign exchange derivatives trading is to effectively hedge against foreign exchange market risks and prevent adverse impacts from significant currency fluctuations [1]. - The company plans to engage with qualified banks and financial institutions to conduct these transactions [1]. Group 2: Basic Details of the Trading Business - The company intends to utilize its own funds for foreign exchange derivatives trading, with a total limit not exceeding $50 million [2]. - The expected maximum margin and premium for these transactions will not exceed $4 million [2]. - The trading will involve currencies used in the company's overseas operations, primarily the US dollar, and will include various products such as forward foreign exchange settlements, foreign exchange swaps, and options [1][2]. Group 3: Risk Management Measures - The company will adhere to principles of legality, prudence, safety, and effectiveness in its trading activities, avoiding speculative transactions [4][8]. - A clear set of operational norms, approval authorities, and risk management procedures will be established to control trading risks [8]. Group 4: Impact on the Company - The foreign exchange derivatives trading is closely related to the company's operational activities, enhancing its ability to manage foreign exchange risks and reducing financial costs [5][10]. - The trading activities are expected to strengthen the company's financial stability without harming the interests of the company or its shareholders [5][10]. Group 5: Accounting Policies and Procedures - The company will follow relevant accounting standards for financial instruments and hedge accounting to reflect the transactions in its financial statements [9]. Group 6: Approval Process - The board of directors approved the continuation of foreign exchange derivatives trading on August 20, 2025, with the authorization effective from September 23, 2025, for a period of 12 months [9][10]. - The audit committee has confirmed the necessity and compliance of the decision-making process regarding the trading activities [10].

Group 1 - The core viewpoint of the article is that Guangkang Biochemical (300804.SZ) reported significant growth in its financial performance for the first half of 2025, indicating a strong operational performance [1] Group 2 - The company achieved operating revenue of 399 million yuan, representing a year-on-year increase of 25.55% [1] - The net profit attributable to shareholders of the listed company was 29.01 million yuan, showing a year-on-year growth of 32.13% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 27.48 million yuan, with a remarkable year-on-year increase of 190.00% [1] - The basic earnings per share were reported at 0.3921 yuan [1]